ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "clinical trials"

  • Abstract Number: 028 • 2020 Pediatric Rheumatology Symposium

    A Randomized, Double-blind, Placebo-controlled Study of Anakinra in Pediatric and Adult Patients with Still’s Disease

    Laura Schanberg1, Peter Nigrovic 2, Ashley Cooper 3, Winn Chatham 4, Shoghik Akoghlanian 5, Namrata Singh 6, C. Egla Rabinovich 7, Akaluck Thatayatikom 8, Alysha Taxter 9, Jonathan Hausmann 10, Milan Zdravkovic 11, Sven Ohlman 11, Henrik Andersson 11, Susanna Cederholm 12, Gunilla Huledal 11, Rayfel Schneider 13 and Fabrizio De Benedetti 14, 1Duke Children's Hospital & Health Center, Durham, North Carolina, 2Boston Children's Hospital, Boston, Massachusetts, 3Children's Mercy Kansas City, Kansas City, 4University of Alabama at Birmingham, Birmingham, 5Nationwide Children's Hospital, Columbus, 6University of Iowa Hospitals and Clinics, Iowa, Iowa, 7Duke University Hospital, Durham, 8University of Florida, Gainesville, 9Wake Forest Baptist Medical Center, Winston-Salem, 10Division of Immunology, Boston Children's Hospital; Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, 11Sobi, Stockholm, Sweden, 12Stockholm, Sweden, 13The Hospital for Sick Children, Toronto, Canada, 14Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Italy

    Background/Purpose: Adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) are rare systemic disorders of auto-inflammatory nature. There is a growing understanding that SJIA…
  • Abstract Number: L18 • 2019 ACR/ARP Annual Meeting

    A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study

    Di Wu1, Jing Li 2, Dong Xu 2, Wenxiang Wang 3, Lin Li 4, Jianmin Fang 3 and Fengchun Zhang 5, 1Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), 2Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Beijing, China (People's Republic), 3RemeGen, Ltd., Yantai, China (People's Republic), 4RemeGen, Ltd., Beijing, China (People's Republic), 5Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)

    Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…
  • Abstract Number: L21 • 2019 ACR/ARP Annual Meeting

    Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study

    Atul Deodhar1, Ricardo Blanco 2, Eva Dokoupilova 3, Marleen van de Sande 4, Stephen Hall 5, Anna Wiksten 6, Brian Porter 7, Hanno Richards 6, Sibylle Haemmerle 6 and Jürgen Braun 8, 1Oregon Health & Science University, Portland, OR, 2Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 3MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, 4Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, 5Monash University, Melbourne, Australia, 6Novartis Pharma AG, Basel, Switzerland, 7Novartis Pharmaceuticals Corporation, East Hanover, NJ, 8Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

    Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
  • Abstract Number: 930 • 2019 ACR/ARP Annual Meeting

    Neurostimulation for Treatment of Drug Refractory Rheumatoid Arthritis: A First-in-Human Study Using a Novel Vagus Nerve Stimulator

    Norman Gaylis1, David Sikes 2, Alan Kivitz 3, Diane Horowitz 4, Charles Peterfy 5, Yaakov Levine 6, David Chernoff 6 and Mark Genovese 7, 1Arthritis and Rheumatic Disease Specialties, Aventura, FL, 2Florida Medical Clinic, Land O Lakes, FL, 3Altoona Center for Clinical Research, Duncansville, PA, 4Northwell Health, Manhasset, NY, 5Spire Sciences Inc, Boca Raton, 6SetPoint Medical, Valencia, CA, 7Stanford University, Stanford, CA

    Background/Purpose: The inflammatory reflex is an endogenous neuroimmune circuit that helps regulate innate and adaptive immunity (Annu. Rev. Immunol. 2012; 30:313). Activation of this reflex by…
  • Abstract Number: 1694 • 2019 ACR/ARP Annual Meeting

    Pharmacogenetics and Pharmacodynamics of Response to Apremilast in a Phase 3 Clinical Study in Subjects with Active Behçet’s Disease

    Joseph Maranville1, Irina Medvedeva 1, Robert Yang 1, Mindy Chen 2, Lorraine (Ruoying) Fang 2, Sandra Collazo 3, Shannon McCue 3, Marla Hochfeld 3 and Peter Schafer 3, 1Celgene Corporation, Cambridge, MA, 2Celgene Corporation, Berkeley Heights, NJ, 3Celgene Corporation, Summit, NJ

    Background/Purpose: This was an exploratory analysis of genetic polymorphisms, plasma biomarkers, and blood leukocytes with clinical response in the phase 3 clinical study CC-10004-BCT-002 (NCT02307513).Methods:…
  • Abstract Number: 937 • 2019 ACR/ARP Annual Meeting

    Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study

    Désirée van der Heijde1, Lianne Gensler 2, Atul Deodhar 3, Xenofon Baraliakos 4, Denis Poddubnyy 5, Alan Kivitz 6, Marga Oortgiesen 7, Dominique Baeten 8, Nadine Goldammer 9, Jason Coarse 7, MK Farmer 7 and Maxime Dougados 10, 1Leiden University Medical Center, Leiden, Netherlands, 2University San Francisco California, San Francisco, CA, 3Oregon Health & Science University, Portland, OR, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, 6Altoona Center for Clinical Research, Duncansville, PA, 7UCB Pharma, Raleigh, NC, USA, Raleigh, NC, 8UCB Pharma, Brussels, Belgium, Brussels, 9UCB Pharma, Monheim, Germany, Monheim, Germany, 10Cochin Hospital, Paris, France

    Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
  • Abstract Number: 1697 • 2019 ACR/ARP Annual Meeting

    Efficacy of Apremilast for Oral Ulcers Associated with Active Behçet’s Syndrome over 64 Weeks: Long-term Results from the Japanese Subgroup in a Phase III Study

    Mitsuhiro Takeno1, Yoshiya Tanaka 2, Hajime Kono 3, Shoji Sugii 4, Mitsumasa Kishimoto 5, Sue Cheng 6, Shannon McCue 7, Mindy Chen 8, Maria Paris 6 and Hiroaki Dobashi 9, 1Nippon Medical School, Tokyo, Japan, 2University of Occupational and Environmental Health Japan, Kitakyushu, Japan, 3Teikyo University School of Medicine, Tokyo, Japan, 4Department of Rheumatic Diseases, Tokyo Metropoitan Tama Medica Center, Fuchu, Japan, 5Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, 6Celgene Corporation, Summit, 7Celgene Corporation, Summit, NJ, 8Celgene Corporation, Berkeley Heights, NJ, 9Kagawa University, Kagawa, Japan

    Background/Purpose: Behçet’s syndrome is a chronic, multi-system, variable vessel vasculitis characterized by painful, recurrent oral ulcers (OU) that can be disabling and may impair quality…
  • Abstract Number: 940 • 2019 ACR/ARP Annual Meeting

    Response to Placebo in Randomized Clinical Trials with Biologics in Non-renal, Non-neuropsychiatric Systemic Lupus Erythematosus: A Systematic Review and Pooled Analysis

    Konstantinos Tselios1, Laura Wakani 2, Dafna Gladman 3, Jiandong Su 4 and Murray Urowitz 4, 1University Health Network, University of Toronto, Toronto, Canada, 2University Health Network, Toronto, Canada, 3Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 4University Health Network, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Most randomized controlled trials (RCTs) with biologic medicines in systemic lupus erythematosus (SLE) failed to reach their respective end-points with the rates of the…
  • Abstract Number: 1760 • 2019 ACR/ARP Annual Meeting

    Six-week Treatment with Low-dose Prednisolone in Patients with Painful Hand Osteoarthritis (HOPE): Results from a Randomised Double-blind Placebo-controlled Trial

    Féline Kroon1, Marion Kortekaas 1, Annelies Boonen 2, Stephan Böhringer 3, Monique Reijnierse 1, Frits R Rosendaal 3, Naghmeh Riyazi 4, Mirian Starmans 5, Franktien Turkstra 6, Jende van Zeben 7, CF Allaart 8 and Margreet Kloppenburg 3, 1Leiden University Medical Center, Leiden, Netherlands, 2Maastricht University Medical Center, Maastricht, Netherlands, 3Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, 4Haga Hospital, The Hague, Netherlands, 5Zuyderland Medical Center, Heerlen, Netherlands, 6Amsterdam Rheumatology and immunology Center | Reade, Amsterdam, Netherlands, 7Sint Franciscus Vlietland Groep, Rotterdam, Netherlands, 8Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands

    Background/Purpose: Hand osteoarthritis (OA) is a prevalent joint disease with high disease-burden in need for effective therapeutic options. Studies have shown that synovial inflammation is…
  • Abstract Number: 941 • 2019 ACR/ARP Annual Meeting

    Treatment of Lupus Nephritis with anti-CD20 Followed by Anti-BAFF: Impact on B Cell Reconstitution, B Cell Subsets, and Autoreactivity

    Yemil Atisha Fregoso1, Susan Malkiel 2, Kristina Harris 3, Sai Kanaparthi 3, Margie Byron 4, Linna Ding 5, Dawn Smilek 6, David Wofsy 7, Maria Dall'Era 8, Cynthia Aranow 1 and Betty Diamond 9, 1Feinstein Institute for Medical Research, Manhasset, NY, 2Feinstein Institute for Medical Research, Manhasset, 3Immune Tolerance Network, Bethesda, 4Rho Federal Systems, Inc., Chapel Hill, NC, 5National Institute of Allergy and Infectious Diseases, Bethesda, MD, 6Immune Tolerance Network, San Francisco, CA, 7UCSF, San Francisco, 8University of California, San Francisco, San Francisco, CA, 9Feinstein Institutes for Medical Research, Manhasset

    Background/Purpose: Despite the relevance of B cells in lupus, two clinical trials of anti-CD20 failed to meet primary endpoints in patients with lupus and lupus…
  • Abstract Number: 2174 • 2019 ACR/ARP Annual Meeting

    Test-Retest Reliability and Validity of a Mobile Health Application to Automate the 30 Seconds Chair Stand Test – Preliminary Data to Create a Contemporary Instrument for Randomized Clinical Trials

    Lucas Dantas1, Matthew Harkey 2, André Dantas 3, Lori Lyn Price 4, Jeffrey Driban 5 and Timothy McAlindon 1, 1Tufts Medical Center, Boston, MA, 2Tufts Medical Center, University of Massachusetts Medical School, Boston, MA, 3CI&T, Tokyo, Japan, 4Tufts Medical Center, Tufts University, Boston, MA, 5Tufts Medical Center, Boston

    Background/Purpose: Contemporary technologies offer potential solutions to improve and automate data collection of randomized clinical trials by transitioning assessments from the clinic to the real-world.…
  • Abstract Number: 946 • 2019 ACR/ARP Annual Meeting

    Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study

    Gulen Hatemi1, Alfred Mahr 2, Mitsuhiro Takeno 3, Doyoung Kim 4, Melike Melikoglu 5, Sue Cheng 6, Shannon McCue 7, Maria Paris 6, Mindy Chen 8 and Yusuf Yazici 9, 1Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, 2Hospital Saint-Louis, University Paris Diderot, Paris, France, 3Nippon Medical School, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University – Cerrahpasa, Behçet’s Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, 6Celgene Corporation, Summit, 7Celgene Corporation, Summit, NJ, 8Celgene Corporation, Berkeley Heights, NJ, 9New York University School of Medicine, New York

    Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful, recurrent oral ulcers (OU) that can impair quality of life (QoL). Apremilast (APR),…
  • Abstract Number: 2710 • 2019 ACR/ARP Annual Meeting

    Sarilumab, a Human Monoclonal Antibody to the Interleukin-6 Receptor, in Polyarticular-course Juvenile Idiopathic Arthritis: A 12-week, Multinational, Open-label, Dose-finding Study

    Fabrizio De Benedetti1, Inmaculada Calvo Penadés 2, Nadina Rubio-Pérez 3, Alexey Maschan 4, Pierre Quartier 5, Zbigniew Żuber 6, Marina Stanislav 7, Raul Barria 8, Daniel Clemente 9, Gabriel Vega-Cornejo 10, Nancy Liu 11, Christine Xu 11, Angeliki Giannelou 12, Bolanle Akinlade 12 and Lydie Baret-Cormel 13, 1Bambino Gesù Children’s Hospital, Rome, Italy, 2Hospital Univ. La Fe, Valencia, Spain, 3University Hospital Dr. José Eleuterio González, Monterrey, Mexico, 4Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia, 5Necker Hospital, Paris, France, 6Andrzej Frycz Modrzewski Krakow University, Kraków, Poland, 7V.A. Nasonova Research Rheumatology Institute, Moscow, Russia, 8Bioreuma, Concepción, Chile, 9Hospital Infantil Universitario Niño Jesús, Madrid, Spain, 10CREA de Guadalajara, Jalisco, Mexico, 11Sanofi, Bridgewater, NJ, 12Regeneron, New York, NY, 13Sanofi, Chilly-Mazarin, France

    Background/Purpose: Sarilumab blocks interleukin-6 (IL-6) from binding to membrane and soluble IL-6 receptor-α. Sarilumab is approved for adults with rheumatoid arthritis (RA) and is being…
  • Abstract Number: 1144 • 2019 ACR/ARP Annual Meeting

    Understanding Clinical Trials Participation Among Individuals of African Descent with Lupus Through the Lens of Critical Race Theory: A Qualitative Analysis

    Candace Feldman1, Jessica Williams 1, Courtnie Phillip 1, Corine Sinnette 1, Karen Mancera-Cuevas 2, Patricia Canessa 3, Gina Curry 4, Maryann Mason 2 and Rosalind Ramsey-Goldman 2, 1Brigham and Women's Hospital, Boston, MA, 2Northwestern University, Chicago, IL, 3IPHA, Chicago, IL, 4University of Chicago, Chicago, IL

    Background/Purpose: Despite a disproportionate burden of lupus and poorer outcomes among individuals of African descent (hereafter “black”) compared to white individuals, black individuals are underrepresented…
  • Abstract Number: 2771 • 2019 ACR/ARP Annual Meeting

    A Phase I, Randomized, Double-blind, Placebo-controlled, Single Center, Single-dose Escalation to Investigate the Safety, Tolerability, and Pharmacodynamics of Subcutaneously Administered DEN-181 in Adult Patients with ACPA+ Rheumatoid Arthritis on Stable Methotrexate

    Amee Sonigra 1, Hendrik Nel 2, Nishta Ramnoruth 2, Meghna Talekar 2, Joanne Tesiram 3, Frederik Stuurman 4, Lavinia Proctor 5, Helen Roberts 6, Robin Thurmond 7, Phillip Vecchio 3, Ian Gourley 8, Mark Rigby 9, Nathan Felix 10, Stephane Becart 11, Kim Campbell 12 and Ranjeny Thomas2, 1Princess Alexandra Hospital, Woolloongabba, Queensland, Australia, 2University of Queensland, Woolloongabba, Australia, 3Princess Alexandra Hospital, Woolloongabba, Australia, 4Centre for Human Drug Research, Leiden, Netherlands, 5Dendright, Woolloongabba, Australia, 6Dendright, Woolloongabba, Queensland, Australia, 7Janssen Research & Development, La Jolla, CA, 8Janssen Research & Development, Springhouse, 9Janssen Research & Development, La Jolla, 10Janssen R&D, Spring House, PA, 11Janssen R&D, La Jolla, CA, 12Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Antigen-specific immunological tolerance strategies leverage the natural process of antigen presentation by dendritic cells (DCs) to regulate pathogenic T cells and B cells. We…
  • 1
  • 2
  • 3
  • …
  • 14
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology